Skip to main content
. 2014 Mar 10;5(6):1538–1553. doi: 10.18632/oncotarget.1754

Figure 4. Effects of uPAR silencing with uPAR-aODN on invasion and small Rho-GTPases activation in mesenchymal and amoeboid conditions of prostate and melanoma cancer cells.

Figure 4

Panel A: Western Blotting analysis of uPAR for each prostate cancer and melanoma cell line after uPAR-aODN treatment. DOTAP: treatment of cells with the cationic liposome alone; aODN: treatment of cells with DOTAP liposomes-delivered uPAR-antisense oligodeoxynucleotide; sODN: treatment of cells with DOTAP liposomes-delivered scramble oligodeoxynucleotide. Numbers on the right of each Western blotting refer to molecular weights expressed in kDa. GAPDH used as a reference loding control. Panel B: Matrigel invasion under mesenchymal (-MIX) and amoeboid (+MIX) conditions. Results are the mean of three experiments performed in triplicate on each cell line ± SD. * : p<0.05 with respect to controls. Panel C: Western blotting of total and GTP-loaded forms of small Rho-GTPases RhoA and Rac1 under mesenchymal and amoeboid conditions for each prostate cancer and melanoma cell line, untreated and treated with aODN/sODN, respectively. Histograms report RhoA/Rac1 ratio obtained by band densitometry quantification. *: statistical significance at p<0.05 with respect to control; **: statistical significance at p<0.01 with respect to controls. Numbers on the right of each Western blotting refer to molecular weights expressed in kDa. For other symbols, refer to the legend of figure 1.